Hyderabad-based Transgene Biotek has obtained a license to manufacture 20 million doses each of Human Tissue Plasminogen Activator and Recombinant Interferon Beta I B (IFNbIB) annually.

Transgene has been focusing on the development, production and commercialization of human therapeutic proteins to be used in various medical conditions.

The proteins under the umbrella of the company are recombinant Erythropoietin, Interferon Alpha II b followed by two more therapeutic proteins in Phase II. Transgene’s core strength in the development of these products lies in developing a technology process facilitating high yield of final purified protein so as to make the final drug priced competitively.

The use of recombinant DNA technology to manufacture therapeutic proteins has been a major breakthrough for the pharmaceutical industry. Many different recombinant proteins have emerged, either for therapeutic or for diagnostic purposes.

These developments resulted from an ability to understand how to manipulate DNA structure and expression. PCR technologies and the development of efficient expression vectors have enabled scientists in the pharmaceutical-biotechnology industry to obtain high yields of protein from bacteria and now perhaps from plants or even from the milk of animals.